Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351084 | 0.79 | FFAR1 (0.43) | SMN1; SMN2HPGDRAB9ANPC1L3MBTL1 | |
| SCHEMBL348939 | 0.79 | FFAR1 (0.43) | SMN1; SMN2HPGDRAB9ANPC1L3MBTL1 | |
| SCHEMBL351083 | 0.78 | CRHBP (0.47) | SMN1; SMN2HPGDRAB9ANPC1L3MBTL1 | |
| SCHEMBL348938 | 0.78 | CRHBP (0.47) | SMN1; SMN2HPGDRAB9ANPC1L3MBTL1 | |
| SCHEMBL358839 | 0.75 | HPGD (0.43) | SMN1; SMN2HPGDRAB9ANPC1L3MBTL1 | |
| SCHEMBL1891741 | 0.73 | MAPT (0.42) | SMN1; SMN2HPGDRAB9ANPC1L3MBTL1 | |
| SCHEMBL1884906 | 0.73 | MAPT (0.42) | SMN1; SMN2HPGDRAB9ANPC1L3MBTL1 | |
| SCHEMBL1884908 | 0.70 | KMT2A (0.37) | SMN1; SMN2HPGDL3MBTL1MAPTKMT2A | |
| SCHEMBL351929 | 0.68 | CASP3 (0.42) | SMN1; SMN2HPGDRAB9ANPC1L3MBTL1 | |
| SCHEMBL349358 | 0.68 | CASP3 (0.42) | SMN1; SMN2HPGDRAB9ANPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016021-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | XENOPORT, INC. (US) | 2012-01-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016021-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | GABBR2, GABBR1, GABRB1 | SMN1; SMN2 327/4885HPGD 2399/4885RAB9A 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.